Share on StockTwits

Immunogen (NASDAQ:IMGN) has earned an average rating of “Buy” from the thirteen brokerages that are presently covering the stock, Analyst Ratings News reports. Two analysts have rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $17.78.

Shares of Immunogen (NASDAQ:IMGN) traded up 6.51% on Thursday, hitting $12.92. 367,591 shares of the company’s stock traded hands. Immunogen has a 1-year low of $10.69 and a 1-year high of $20.25. The stock has a 50-day moving average of $11.97 and a 200-day moving average of $14.3. The company’s market cap is $1.109 billion.

Immunogen (NASDAQ:IMGN) last posted its quarterly earnings results on Friday, April 25th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by $0.17. The company had revenue of $6.90 million for the quarter, compared to the consensus estimate of $13.28 million. During the same quarter in the previous year, the company posted ($0.02) earnings per share. The company’s revenue for the quarter was down 72.4% on a year-over-year basis. On average, analysts predict that Immunogen will post $-0.84 earnings per share for the current fiscal year.

A number of research firms have recently commented on IMGN. Analysts at Canaccord Genuity initiated coverage on shares of Immunogen in a research note on Wednesday, April 16th. They set a “buy” rating and a $20.00 price target on the stock. Analysts at Zacks upgraded shares of Immunogen from a “neutral” rating to an “outperform” rating in a research note on Monday, April 7th. They now have a $15.90 price target on the stock.

ImmunoGen, Inc (NASDAQ:IMGN) develops targeted, antibody-based therapeutics for the treatment of cancer.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.